Steris Stock (NYSE:STE), Trade Ideas

Steris

Steris is an Ireland-domiciled medical device company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its 2015 inversion to Ireland, the firm continues to derive roughly 70% of revenue from its U.S. operations, 10% from the United Kingdom, and the remaining 20% from other international regions.

Equities

News

Health Care

Markets

General

Becton Dickinson And Company (NYSE: BDX) inked a pact with Steris plc (NYSE: STE) to sell its Surgical Instrumentation platform 

Becton Dickinson Banks $540M With Surgical Unit Sale, 360 Employees To Join Steris

Earnings

Guidance

Movers

Trading Ideas

Steris Delivered Strong Q4 Performance, But Analyst Call FY24 Outlook Mixed

Futures

Economics

Federal Reserve

$BTC

BYND

DNUT

GOOG

GOOGL

HOOD

USFD

US Stocks Dip, Big Tech Holds On Soft PPI, Declining Treasury Yields: Traders Are &#39;All-In&#39; On June Fed Pause

Steris PLC

Stream Media Corp

Scatec ASA

STEER TECHNOLOGIES INC by STEER TECHNOLOGIES INC.

STEER Technologies Inc

Steem

STATE ENERGY GRP by STATE ENERGY GROUP INTL ASSETS HLDGS LTD.

State Energy Group International Assets Holdings Ltd

Sintana Energy Inc Warrants (08/03/2024)

Stemtech Corp

Stellar Bancorp Inc

Stem Inc

StepStone Group Inc. - Class A Common Stock

StepStone Group Inc

Sterling Check Corp

Lido Staked ETH - United States Dollar

ST Energy Transition I Ltd Warrants (02/12/2026)

ST Energy Transition I Ltd

Stevia Corp

SRH Total Return Fund, Inc.

<p>Needham  analyst Mike Matson   reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Hold.</p>


Reiteration

Analyst Ratings

Needham Reiterates Hold on Steris

STERIS shares are trading higher after the company entered a deal to divest its dental segment to Peak Rock Capital for $787.5 million.

<p>The Transaction is structured as an equity sale. The Transaction terms also include the opportunity for STERIS to receive an additional earnout of up to&nbsp;$12.5 million, subject to the achievement of certain revenue targets of the Dental segment in fiscal 2025. The Dental segment reported revenue of&nbsp;$407 million&nbsp;and contributed segment operating income of&nbsp;$86 million&nbsp;in the trailing twelve-month period ended December 31, 2023.&nbsp;The Transaction is&nbsp;anticipated to close in the&nbsp;first quarter&nbsp;of fiscal year 2025. STERIS intends to use the proceeds primarily to repay debt. On a full year run rate basis, STERIS expects the resulting benefit of the reduction in interest expense to be approximately&nbsp;$0.35&nbsp;per diluted share.</p>


Asset Sales

STERIS Enters Definitive Deal To Divest Its Dental Segment To Peak Rock Capital For $787.5M

<p>Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Steris and provided 12-month price targets. The average target is $245.75, accompanied by a high estimate of $265.00 and a low estimate of $215.00. Marking an increase of 9.22%, the current average surpasses the previous average price target of $225.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1707505271_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of Steris among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$250.00</td>
<td>-</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>-</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$253.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$215.00</td>
<td>$225.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Steris. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Steris compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Steris's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Steris's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Steris analyst ratings.</strong></a></p>
<h2>Delving into Steris's Background</h2>
<p>Steris is an Ireland-domiciled medical device company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its 2015 inversion to Ireland, the firm continues to derive roughly 70% of revenue from its U.S. operations, 10% from the United Kingdom, and the remaining 20% from other international regions.</p>
<h3>A Deep Dive into Steris's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Steris displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>3.97%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Steris's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>10.08%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>2.23%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Steris's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>1.24%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Steris's debt-to-equity ratio is below the industry average. With a ratio of <b>0.5</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 4 Analyst Ratings Have To Say About Steris

<p>Stephens &amp; Co.  analyst Jacob Johnson   reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight and maintains $250 price target.</p>


Price Target

Stephens & Co. Reiterates Overweight on Steris, Maintains $250 Price Target

<p>JMP Securities  analyst David Turkaly   reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Market Outperform and maintains $265 price target.</p>


JMP Securities Reiterates Market Outperform on Steris, Maintains $265 Price Target

WIIM

STERIS shares are trading lower after the company reported Q3 financial results.

<p><strong>Steris</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported its Q3 earnings results on Wednesday, February 7, 2024 at 04:30 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Steris beat estimated earnings by 2.3%, reporting an EPS of $2.22 versus an estimate of $2.17.</p>
<p>Revenue was up $180.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.02 which was followed by a 5.46% drop in the share price the next day.</p>
<p>Here's a look at Steris's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.01</td>
<td>1.86</td>
<td>2.15</td>
<td>2.19</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.03</td>
<td>2</td>
<td>2.30</td>
<td>2.02</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.30B</td>
<td>1.19B</td>
<td>1.27B</td>
<td>1.27B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.34B</td>
<td>1.28B</td>
<td>1.39B</td>
<td>1.22B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Steris <a href="https://www.benzinga.com/quote/STE/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: Steris Q3 Earnings

<p>Adjusted earnings per diluted share revised due primarily to a shift in operating income mix from AST to Healthcare.&nbsp;&nbsp;</p>


STERIS Now Expects FY24 As Reported Revenue To Increase 10-11%, Up From Previous Expectations Of 9-10%; Revises Adjusted EPS Outlook From $8.60-$8.80 To $8.60-$8.70 (Est $8.67)

Steris Q3 Sales $1.40B Beat $1.35B Estimate

<p>Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported quarterly Adj earnings of $2.22 per share which beat the analyst consensus estimate of $2.17 by 2.3 percent. This is a 9.9 percent increase over earnings of $2.02 per share from the same period last year.</p>


Steris Q3 Adj EPS $2.22 Beats $2.17 Estimate

ACLS

ADNT

ALCO

APPS

ARCC

ASGN

ASND

AVXL

AZTA

BABA

BARK

BERY

BLBD

CDAY

CENT

CENTA

CFLT

CMRE

COTY

CRTO

CSGS

EEFT

ENTA

EQNR

FLNC

FLNG

FORM

FOXA

GEOS

GPRE

GPRO

HAIN

INTR

MCFT

MKSI

MPWR

MSGE

MTRX

NBIX

NOTV

NTGR

NVST

NWSA

OESX

ORLY

OSCR

PAHC

Earnings Scheduled For February 7, 2024

<p><strong>Steris</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-02-07. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Steris will report an <strong>earnings per share</strong> (EPS) of $2.17. </p>
<p>Steris bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.02, which was followed by a 5.46% drop in the share price the next day.</p>
<p>Here's a look at Steris's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.01</td>
<td>1.86</td>
<td>2.15</td>
<td>2.19</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.03</td>
<td>2</td>
<td>2.30</td>
<td>2.02</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.46%</td>
<td>1.69%</td>
<td>9.83%</td>
<td>-10.89%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1707242525_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Steris were trading at $219.9 as of February 05. Over the last 52-week period, shares are up 4.46%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/STE/earnings"><strong>To track all earnings releases for Steris visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For Steris

<p>Keybanc  analyst Brett Fishbin   initiates coverage on Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight rating and announces Price Target of $253.</p>


Initiation

Keybanc Initiates Coverage On Steris with Overweight Rating, Announces Price Target of $253

<p>At the end of today, December 21, 2023, <b>Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>)</b> will distribute a dividend payout of $0.52 per share, translating to an annualized dividend yield of 0.99%. Shareholders who held the stock before the ex-dividend date on November 20, 2023 will benefit from this payout.</p>
<h3>Steris Recent Dividend Payouts</h3>
<style>
        table {
            width: 100%;
            border-collapse: collapse;
            font-family: Arial, sans-serif;
            font-size: 14px;
        }

        th, td {
            padding: 8px;
            text-align: left;
        }

        th {
            background-color: #293a5a;
            color: #fff;
            text-align: left;
        }

        tr:nth-child(even) {
            background-color: #f2f4f8;
        }

        tr:hover {
            background-color: #e1e4ea;
        }

        td:nth-child(3), td:nth-child(5) {
            text-align: left;
        }

        .dividend-amount {
            font-weight: bold;
            color: #0d6efd;
        }

        .dividend-frequency {
            font-size: 12px;
            color: #6c757d;
        }
    </style><table>
<thead>
<tr>
<th><strong>Ex-Date</strong></th>
<th style="text-align: right;"><strong>Payments per year</strong></th>
<th><strong>Dividend</strong></th>
<th><strong>Yield</strong></th>
<th><strong>Announced</strong></th>
<th><strong>Record</strong></th>
<th><strong>Payable</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>2023-11-20</td>
<td style="text-align: right;">4</td>
<td>$0.52</td>
<td>0.99%</td>
<td>2023-10-31</td>
<td>2023-11-21</td>
<td>2023-12-21</td>
</tr>
<tr>
<td>2023-09-05</td>
<td style="text-align: right;">4</td>
<td>$0.52</td>
<td>0.89%</td>
<td>2023-07-26</td>
<td>2023-09-06</td>
<td>2023-09-22</td>
</tr>
<tr>
<td>2023-06-13</td>
<td style="text-align: right;">4</td>
<td>$0.47</td>
<td>0.99%</td>
<td>2023-05-03</td>
<td>2023-06-14</td>
<td>2023-06-28</td>
</tr>
<tr>
<td>2023-02-23</td>
<td style="text-align: right;">4</td>
<td>$0.47</td>
<td>0.91%</td>
<td>2023-02-01</td>
<td>2023-02-24</td>
<td>2023-03-23</td>
</tr>
<tr>
<td>2022-11-21</td>
<td style="text-align: right;">4</td>
<td>$0.47</td>
<td>1.09%</td>
<td>2022-11-02</td>
<td>2022-11-22</td>
<td>2022-12-16</td>
</tr>
<tr>
<td>2022-09-06</td>
<td style="text-align: right;">4</td>
<td>$0.47</td>
<td>0.85%</td>
<td>2022-07-28</td>
<td>2022-09-07</td>
<td>2022-09-23</td>
</tr>
<tr>
<td>2022-06-13</td>
<td style="text-align: right;">4</td>
<td>$0.43</td>
<td>0.76%</td>
<td>2022-05-04</td>
<td>2022-06-14</td>
<td>2022-06-28</td>
</tr>
<tr>
<td>2022-02-24</td>
<td style="text-align: right;">4</td>
<td>$0.43</td>
<td>0.78%</td>
<td>2022-01-31</td>
<td>2022-02-25</td>
<td>2022-03-24</td>
</tr>
<tr>
<td>2021-11-22</td>
<td style="text-align: right;">4</td>
<td>$0.43</td>
<td>0.74%</td>
<td>2021-10-28</td>
<td>2021-11-23</td>
<td>2021-12-17</td>
</tr>
<tr>
<td>2021-09-02</td>
<td style="text-align: right;">4</td>
<td>$0.43</td>
<td>0.8%</td>
<td>2021-08-09</td>
<td>2021-09-03</td>
<td>2021-09-24</td>
</tr>
<tr>
<td>2021-05-27</td>
<td style="text-align: right;">4</td>
<td>$0.4</td>
<td>0.81%</td>
<td>2021-05-18</td>
<td>2021-05-28</td>
<td>2021-06-25</td>
</tr>
<tr>
<td>2021-02-23</td>
<td style="text-align: right;">4</td>
<td>$0.4</td>
<td>0.86%</td>
<td>2021-02-02</td>
<td>2021-02-24</td>
<td>2021-03-25</td>
</tr>
</tbody>
</table>
<p>Steris's dividend yield falls in the middle range when compared to its industry peers, with <b>Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)</b> having the highest annualized dividend yield at 3.42%.</p>
<h3>Analyzing Steris Financial Health</h3>
<p>Companies that pay out steady cash dividends are attractive to income-seeking investors, and companies that are financially healthy tend to maintain their dividend payout schedule. For this reason, investors can find it insightful to see if a company has been increasing or decreasing their dividend payout schedule and if their earnings are growing. </p>
<h3>YoY Growth in Dividend Per Share</h3>
<p><img src="https://www.benzinga.com/files/images/story/2023/1703171139_0.png" alt="dividend chart graph" /></p>
<p>As you can see, from 2019 to 2022, investors saw an average increase in the company's dividend per share, rising from $1.42 in 2019 to $1.80 in 2022. This is good for investors because it shows that the company has steadily returned more capital back to their shareholders and it could mean that they are planning to continue increasing dividends.</p>
<h3>YoY Earnings Growth For Steris</h3>
<p><img src="https://www.benzinga.com/files/images/story/2023/1703171139_1.png" alt="earning chart graph" /></p>
<p>From 2019 to 2022, Steris has demonstrated an upward trend in earnings, with earnings per share rising from $5.34 to $8.05. This positive earnings growth bodes well for investors looking to generate income through cash dividend payouts.</p>
<h3>Recap</h3>
<p>This article delves into the recent dividend payout of Steris and its implications for shareholders. Presently, the company is distributing a dividend of $0.52 per share, leading to an annualized dividend yield of 0.99%.</p>
<p>Steris's dividend yield falls in the middle range when compared to its industry peers, with Medtronic having the highest annualized dividend yield at 3.42%.</p>
<p>Considering the increase in dividend per share from 2019 to 2022 along with an increase in earnings per share, Steris appears to be in a strong financial position, indicating their ability to sustain dividend distributions to investors.</p>
<p>To stay informed about changes in financials or dividend disbursements, investors should pay close attention to the company's performance in the upcoming quarters.</p>
<p>[See current stock movements Steris on Benzinga.](https://www.benzinga.com/quote/<b>Steris (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ste#NYSE">STE</a>)</b>)</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Dividends

Steris Exceeds Expectations with Strong Performance, Driving Profits and Rewarding Investors

<p>Analysts have provided the following ratings for Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) within the last quarter: </p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>According to 5 analyst offering 12-month price targets in the last 3 months, Steris has an average price target of $232.0 with a high of $265.00 and a low of $215.00. </p>
<p>Below is a summary of how these 5 analysts rated Steris over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock</p>
<p><img src="https://www.benzinga.com/files/images/story/2023/1701702021_0_0.png" alt="price target chart" /></p>
<p>This current average has increased by 4.66% from the previous average price target of $221.67. </p>
<p><a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Steris analyst ratings.</strong></a></p>
<h1>What Are Analyst Ratings?</h1>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations for Steris's Future

<p>Morgan Stanley  analyst Patrick Wood   maintains Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Equal-Weight and lowers the price target from $225 to $215.</p>


Morgan Stanley Maintains Equal-Weight on Steris, Lowers Price Target to $215

STERIS shares are trading lower after the company reported Q2 financial results and issued FY24 EPS guidance.

<p><strong>Fiscal 2024 Outlook</strong><br /><br />The company is confirming its outlook for fiscal 2024 of as reported revenue growth of 9-10% and constant currency organic revenue growth of 6-7%. Adjusted earnings per diluted share are anticipated to be in the range of $8.60 to $8.80. Free cash flow for fiscal 2024 is anticipated to be approximately $685 million.</p>


STERIS Sees FY24 EPS $8.60-$8.80 Vs $8.75 Est.; Revenue Growth Of 9%-10%

Dividend Champion, Contender, And Challenger Highlights: Week Of February 18

Overall market sentiment has been neutral on Steris PLC (STE)  stock lately. STE receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator. Steris PLC has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on STE!See Full STE ReportWhat is Stock Sentiment?When ma

Do Traders Think Steris PLC (STE) Can Turn Around Tuesday?

Dividend Champion, Contender, And Challenger Highlights: Week Of March 17

A rating of 78 puts Steris PLC (STE) near the top of the Medical Devices industry according to InvestorsObserver. Steris PLC's score of 78 means it scores higher than 78% of stocks in the industry. Steris PLC also received an overall rating of 55, putting it above 55% of all stocks. Medical Devices is ranked 74 out of the

Does Steris PLC (STE) Have What it Takes to be in Your Portfolio Friday?

STERIS to divest its dental unit for $787.5M

Steris plc (STE) has shared an update. STERIS Corporation has agreed to sell its Dental business segment to HuFriedy Group Holding LLC for $787.5 m...

Steris Sells Dental Segment to HuFriedy Group with Conditions

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ADC Therapeutics (ADCT – Research Report), Adial P...

Analysts Conflicted on These Healthcare Names: ADC Therapeutics (ADCT), Adial Pharmaceuticals (ADIL) and Steris (STE)

Needham analyst Michael Matson maintained a Hold rating on Steris (STE – Research Report) today. The company's shares opened today at $211.05. Mats...